Preclinical research has shown that CAR T cells directed against the urokinase plasminogen activator receptor can attack both ...

The activation and regulation of T cells are fundamental to immune homeostasis and effective defence mechanisms. Ubiquitin ligases, such as c-Cbl and Cbl-b, serve as pivotal regulators by targeting ...

The TULA family proteins, comprising predominantly TULA-1 (also known as UBASH3A/STS-2) and TULA-2 (UBASH3B/STS-1), are increasingly recognised as pivotal modulators of T cell receptor (TCR) ...

A University of Pennsylvania study has demonstrated that a dual-action lipid nanoparticle can reverse T-cell exhaustion and ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

New research links atopic dermatitis to S1P signalling pathways driving inflammation. Learn how this could shape future ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

In addition to scalability, another opportunity is presented by clinical feasibility and performance. For example, lymphodepletion conditioning, which is a must for ex vivo-engineered CAR-T cells, is ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Cooperation between Finnish and Chinese research groups has opened up new opportunities for developing treatments targeting aggressive acute lymphoblastic leukaemia (T-ALL). A research group led by ...